We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+2.14%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.51B
AUM Growth
-$1.16B
Cap. Flow
+$107M
Cap. Flow %
1.43%
Top 10 Hldgs %
57.63%
Holding
98
New
17
Increased
9
Reduced
16
Closed
9

Top Buys

Rank Stock Value
1
SEPN
Septerna Inc
SEPN
+$165M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$119M
3
ACLX
Arcellx
ACLX
+$80.8M
4
KURA icon
Kura Oncology
KURA
+$64M
5
JANX icon
Janux Therapeutics
JANX
+$63.5M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$230M
2
VRNA
Verona Pharma
VRNA
+$122M
3
EVH icon
Evolent Health
EVH
+$86.8M
4
CGON icon
CG Oncology
CGON
+$52.7M
5
RXRX icon
Recursion Pharmaceuticals
RXRX
+$51.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.36%
2 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLYS icon
26
Mineralys Therapeutics
MLYS
$2.25B
$59.7M 0.79%
4,850,984
– –
PRAX icon
27
Praxis Precision Medicines
PRAX
$8.58B
$58.6M 0.78%
761,955
– –
CLYM
28
Climb Bio
CLYM
$681M
$56.6M 0.75%
31,419,267
– –
RXRX icon
29
Recursion Pharmaceuticals
RXRX
$1.59B
$52.2M 0.7%
7,725,096
-7,659,519
-50% -$51.5M
TRML
30
DELISTED
Tourmaline Bio
TRML
$51.5M 0.69%
2,538,925
– –
ACRV icon
31
Acrivon Therapeutics
ACRV
$64.2M
$50.2M 0.67%
8,340,508
– –
FULC icon
32
Fulcrum Therapeutics
FULC
$273M
$48.1M 0.64%
10,229,099
– –
TXG icon
33
10x Genomics
TXG
$6B
$47.1M 0.63%
+3,279,401
New +$51.8M
GHRS icon
34
GH Research
GHRS
$1.93B
$46.8M 0.62%
6,686,689
– –
ATXS
35
DELISTED
Astria Therapeutics
ATXS
$45.6M 0.61%
5,105,213
– –
VOR icon
36
Vor Biopharma
VOR
$1.15B
$44M 0.59%
1,982,302
+844,858
+74% +$14M
GPCR icon
37
Structure Therapeutics
GPCR
$3.41B
$41.2M 0.55%
1,517,418
-379,354
-20% -$13.5M
DNTH icon
38
Dianthus Therapeutics
DNTH
$5.84B
$40.7M 0.54%
1,866,400
-466,600
-20% -$12M
PEPG icon
39
PepGen
PEPG
$122M
$40.5M 0.54%
10,689,545
– –
EVH icon
40
Evolent Health
EVH
$348M
$40.2M 0.54%
3,577,197
-4,937,665
-58% -$86.8M
KURA icon
41
Kura Oncology
KURA
$800M
$38.8M 0.52%
+4,451,041
New +$64M
IDYA icon
42
IDEAYA Biosciences
IDYA
$3.42B
$34.6M 0.46%
1,347,252
– –
ZLAB icon
43
Zai Lab
ZLAB
$2.06B
$33.9M 0.45%
+1,295,040
New +$35.9M
CMRX
44
DELISTED
Chimerix, Inc.
CMRX
$30.6M 0.41%
8,800,000
– –
CDTX
45
DELISTED
Cidara Therapeutics
CDTX
$29.4M 0.39%
1,092,796
+389,716
+55% +$6.33M
MBX
46
MBX Biosciences
MBX
$3.14B
$27.9M 0.37%
1,511,334
– –
NKTX icon
47
Nkarta
NKTX
$150M
$26.9M 0.36%
10,805,129
– –
ABOS icon
48
Acumen Pharmaceuticals
ABOS
$155M
$25.7M 0.34%
14,932,063
– –
FDMT icon
49
4D Molecular Therapeutics
FDMT
$532M
$25.4M 0.34%
4,563,211
-535,000
-10% -$4.2M
NRIX icon
50
Nurix Therapeutics
NRIX
$2.41B
$25.1M 0.33%
+1,333,333
New +$30.6M
1
2
3 4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, RA Capital Management held 98 positions worth $7.51B, down 13% from $8.67B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

RA Capital Management's Q4 2024 filing shows 17 new, 9 increased, 16 reduced and 9 closed positions. Its largest new stake was Septerna Inc: 6,995,858 shares worth $160M. The largest sale was Biogen, an estimated $230M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Financials.

  • RA Capital Management's largest Q4 2024 buy was Septerna Inc: 6,995,858 shares worth $160M.
  • RA Capital Management added most to Arcellx in Q4 2024, an estimated $80.8M increase.
  • RA Capital Management's biggest Q4 2024 reduction was Verona Pharma, cutting an estimated $122M.
  • RA Capital Management fully exited Biogen in Q4 2024, selling an estimated $230M.
  • RA Capital Management's ten largest holdings make up 58% of its $7.51B portfolio in Q4 2024.
  • RA Capital Management opened 17 new positions and closed 9 in Q4 2024.
  • RA Capital Management's portfolio value fell 13% quarter-over-quarter to $7.51B.

Based on RA Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.